IPSC‐based modeling of THD recapitulates disease phenotypes and reveals neuronal malformation

Tyrosine hydroxylase deficiency (THD) is a rare genetic disorder leading to dopaminergic depletion and early-onset Parkinsonism. Affected children present with either a severe form that does not respond to L-Dopa treatment (THD-B) or a milder L-Dopa responsive form (THD-A). We generated induced plur...

Descripción completa

Detalles Bibliográficos
Autores: Tristá Noguero, Alba, Fernández Carasa, Irene, Calatayud, Carles, Bermejo Casadesús, Cristina, Pons Espinal, Meritxell, Colini Baldeschi, Arianna, Campa, Leticia, Artigas Pérez, Francesc, Bortolozzi, Analia, Domingo Jiménez, Rosario, Ibáñez, Salvador, Pineda, Mercè, Artuch Iriberri, Rafael, Raya Chamorro, Ángel, García Cazorla, Àngels, Consiglio, Antonella
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/198344
Acceso en línea:https://hdl.handle.net/2445/198344
Access Level:acceso abierto
Palabra clave:Malalties rares
Cèl·lules mare
Fenotip
Dopamina
Rare diseases
Stem cells
Phenotype
Dopamine
Descripción
Sumario:Tyrosine hydroxylase deficiency (THD) is a rare genetic disorder leading to dopaminergic depletion and early-onset Parkinsonism. Affected children present with either a severe form that does not respond to L-Dopa treatment (THD-B) or a milder L-Dopa responsive form (THD-A). We generated induced pluripotent stem cells (iPSCs) from THD patients that were differentiated into dopaminergic neurons (DAn) and compared with control-DAn from healthy individuals and gene-corrected isogenic controls. Consistent with patients, THD iPSC-DAn displayed lower levels of DA metabolites and reduced TH expression, when compared to controls. Moreover, THD iPSC-DAn showed abnormal morphology, including reduced total neurite length and neurite arborization defects, which were not evident in DAn differentiated from control-iPSC. Treatment of THD-iPSC-DAn with L-Dopa rescued the neuronal defects and disease phenotype only in THDA-DAn. Interestingly, L-Dopa treatment at the stage of neuronal precursors could prevent the alterations in THDB-iPSC-DAn, thus suggesting the existence of a critical developmental window in THD. Our iPSC-based model recapitulates THD disease phenotypes and response to treatment, representing a promising tool for investigating pathogenic mechanisms, drug screening, and personalized management.